ArticleCurrent breast cancer reports2013
Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.
Article in Current breast cancer reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Does microtubule motor-mediated centrosomal dyshomeostasis confer chemoresistance in breast cancer?Journal of mammary gland biology and neoplasia · 2025Pooled it
- Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer.Cancer chemotherapy and pharmacology · 2020Trial
- Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.Breast cancer research and treatment · 2014Trial
- Oncogenic cell fate decision in breast epithelial cells I: growth factors and mechanisms.Research square · 2026Article
- Modern synthetic pathways towards eribulin and its subunits.Beilstein journal of organic chemistry · 2026Review
- Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.Breast cancer research and treatment · 2023Article
- Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer.Pharmaceutics · 2023Review
- Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway.Neoplasia (New York, N.Y.) · 2022Article
- Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes.Pharmaceutics · 2021Review
- Emerging strategies for treating metastasis.Nature cancer · 2021Article
- Effect of Hydrophobicity on the Anticancer Activity of Fatty-Acyl-Conjugated CM4 in Breast Cancer Cells.ACS omega · 2020Article
- Anticancer bioactive peptide combined with docetaxel and its mechanism in the treatment of breast cancer.Experimental and therapeutic medicine · 2020Article
- Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.Drugs · 2020Review
- Correlation Between Gamma-Glutamyl Transferase Activity and Glutathione Levels in Molecular Subgroups of Breast Cancer.European journal of breast health · 2020Article
- Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer.Journal of Cancer · 2020Article
- Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.Cancer medicine · 2018Article
- Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment.Saudi journal of biological sciences · 2018Article
- Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.PloS one · 2017Article
- A network-based pathway-expanding approach for pathway analysis.BMC bioinformatics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Anthracyclines and taxanes are cytotoxic agents that are commonly used for the treatment of breast cancer, including in the adjuvant, neoadjuvant, and metastatic setting. Each drug class of is associated with cumulative and potentially irreversible toxicity, including cardiomyopathy (anthracyclines) and neuropathy (taxanes). This may either limit the duration of therapy for advanced disease, or prevent retreatment for recurrence if previously used as component of adjuvant or neoadjuvant therapy. Several classes of cytotoxic agents have been evaluated in patients with anthracycline and taxane-pretreated metastatic breast cancer (MBC), including other antitubulins (vinorelbine, ixabepilone, eribulin), antimetabolites (capecitabine, gemcitabine), topoisomerase I inhibitors (irinotecan), platinum analogues (cisplatin, carboplatin), and liposomal doxorubicin preparations. No trials have shown an overall survival advantage for combination chemotherapy in this setting, indicating that single cytotoxic agents should usually be used, expect perhaps in patients with rapidly progressive disease and/or high tumor burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.